Using GANs for De Novo Protein Design Targeting Microglial IL-3R$α$ to Inhibit Alzheimer's Progression

Arnav Swaroop

Home/Archive/arXiv

arXiv · 2405.06651

Using GANs for De Novo Protein Design Targeting Microglial IL-3R$α$ to Inhibit Alzheimer's Progression

Arnav Swaroop

View original source ↗Read source document ↗Export metadata ↓

Abstract

IL-3 is a hemopoietic growth factor that usually targets blood cell precursors; IL-3R is a cytokine receptor that binds to IL-3. However, IL-3 takes on a different role in the context of glial cells in the nervous system, where studies show that the protein IL-3 protects against Alzheimer's disease by activating microglia at their IL-3R receptors, causing the microglia to clear out the tangles caused by the build-up of misfolded Tau proteins. In this study, we seek to ascertain what role the secondary structure of IL-3 plays in its binding with the receptor. The motivation behind this study is to learn more about the mechanism and identify possible drugs that might be able to activate it, in hopes of inhibiting the spread of Alzheimer's Disease. From a preliminary analysis of complexes containing IL-3 and IL-3R, we hypothesized that the binding is largely due to the interactions of three alpha helix structures stretching towards the active site on the receptor. The original Il-3 protein serves as the control in this experiment; the other proteins being tested are generated through several types of computational de novo protein design, where machine learning allows for the production of entirely novel structures. The efficacy of the generated proteins is assessed through docking simulations with the IL-3R receptor, and the binding poses are also qualitatively examined to gain insight into the function of the binding. From the docking data and poses, the most successful proteins were those with similar secondary structure to IL-3.

Explore related subjects

q-bio.BM cs.LG q-bio.NC

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Arnav Swaroop. 2024-04-05. Using GANs for De Novo Protein Design Targeting Microglial IL-3R$α$ to Inhibit Alzheimer's Progression. https://arxiv.org/abs/2405.06651

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

In Vivo Length Distributions as Mechanistic Fingerprints of Pathological Protein Aggregation

Modern imaging techniques can resolve individual pathological protein aggregates in postmortem human samples, providing detailed measurements of aggregate size distributions that are inaccessible with conventional bulk approaches. These distributions represent mechanistic fingerprints of the microscopic processes that generated the observed pathology, but extracting this mechanistic information requires a quantitative theoretical framework. Here, we develop the mathematical tools needed to interpret aggregate length distributions in living systems, where aggregate growth competes with active removal. We show that, across a class of models, the length distribution of sufficiently large aggregates approaches a geometric decay. Crucially, the decay rate is determined by the balance between aggregate elongation and removal, providing a direct quantitative readout of these competing processes from a single time point measurement. This enables mechanistic comparisons between healthy and diseased human samples without requiring longitudinal measurements of aggregate dynamics. We further analyse how additional aggregation and removal processes modify the observed length distributions. Together, these results establish the mathematical foundations and tools to use aggregate length distributions as an experimentally accessible route for inferring microscopic aggregation dynamics directly from human tissue.

q-bio.BM↗

arXiv2026

Decoding enzyme-substrate interaction topology reveals principles underlying catalytic efficiency and mutational outcomes

The enzyme turnover number (kcat) defines catalytic efficiency and constrains quantitative models of metabolism, yet the molecular determinants governing kcat and its response to mutation remain poorly understood. Measurements are sparse and labor-intensive, and most computational approaches provide numerical predictions without explaining how enzyme-substrate interactions shape catalytic outcomes. A central challenge is therefore to identify the topological principles that determine where mutations act and how their functional outcomes are encoded within the enzyme-substrate interaction network. Here, we show that catalytic efficiency and mutational effects can be interpreted through enzyme-substrate interaction topology. We developed Interkcat, an interpretable bidirectional cross-attention framework that captures reciprocal coordination between protein residues and substrate atoms. Optimized on a unified benchmark, Interkcat achieves state-of-the-art predictive performance (R2 = 0.701). From its learned representations, we derive an Interaction Topology Score (ITS) that identifies sequence regions statistically enriched for mutation-sensitive sites without explicit structural inputs. We further demonstrate that higher-order topological features distinguish opposing mutational outcomes: lethal mutations disrupt coordinated networks, whereas activity-preserving or enhancing mutations retain sparse, globally organized coupling. These findings establish interaction topology as a unifying principle linking enzyme sequence, catalytic efficiency, and evolutionary perturbation.

q-bio.BM↗

arXiv2026

Adapting Boltz-2 with limited experimental activity data improves early enrichment in virtual screening

Virtual screening aims to prioritize active compounds from large chemical libraries within a limited experimental budget. When applying Boltz-2 to virtual screening, a key challenge is how to use limited experimental data from the target assay to improve the prioritization of active compounds. We investigated whether fine-tuning the Boltz-2 affinity heads with a small number of binary activity labels could improve early enrichment of active compounds in hit discovery. We compared fine-tuning with 40-300 labels in a retrospective evaluation on eight MF-PCBA targets. With 300 activity measurements, fine-tuning increased the number of actives in the top 1% by a geometric mean of 1.77-fold across the eight targets and improved average precision (AP) by 2.14-fold relative to the control without fine-tuning. We also investigated whether rescoring a subset of candidates could retain the improvement in hit recovery by reranking only the top-ranked Boltz-2 candidates with the fine-tuned head. Restricting rescoring to approximately 10% of the evaluation set retained hit recovery comparable to full rescoring. These findings show that affinity-head fine-tuning with limited activity labels improves early enrichment with Boltz-2 and that this benefit can be retained when rescoring a restricted set of candidates.

q-bio.BM↗